ID

6181

Description

ODM derived from http://clinicaltrials.gov/ct2/show/record/NCT00952588

Link

http://clinicaltrials.gov/ct2/show/record/NCT00952588

Keywords

Versions (4)
  1. 11/14/11 11/14/11 -
  2. 12/6/13 12/6/13 - Martin Dugas
  3. 4/11/14 4/11/14 - Julian Varghese
  4. 12/16/14 12/16/14 - Martin Dugas
Uploaded on

December 16, 2014

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility AZD1152 and LDAC in AML

English

Eligibility AZD1152 and LDAC in AML

1 forms  
Inclusion criteria
Description

Inclusion criteria

Alias
UMLS CUI-1
C1512693
Provision of written informed consent
Description

consent

Data type

boolean

Alias
UMLS CUI-1
C0021430
Newly diagnosed male or female patients aged 60 and over
Description

Newly diagnosed patients aged 60 and over

Data type

boolean

Alias
UMLS CUI-1
C0001779
De Novo or Secondary AML
Description

De Novo or Secondary AML

Data type

boolean

Alias
UMLS CUI-1
C0023467
Not eligible for intensive induction with anthracycline-based combination chemotherapy as a result of at least one of the following: Age >=75 years; Adverse cytogenetics, e.g., as defined by the MRC Prognostic Groupings; WHO performance status >2; Organ dysfunction arising from significant co-morbidities not directly linked to leukaemia
Description

Not eligible for intensive induction with anthracycline-based combination chemotherapy as a result of at least one of the following: Age >=75 years; Adverse cytogenetics, e.g., as defined by the MRC Prognostic Groupings; WHO performance status >2; Organ dysfunction arising from significant co-morbidities not directly linked to leukaemia

Data type

boolean

Alias
UMLS CUI-1
C3242266
UMLS CUI-2
C0600558
Exclusion criteria
Description

Exclusion criteria

Alias
UMLS CUI-1
C0680251
Participation in another clinical study in which an investigational product was received within 14 days before the first dose in this study, or at any time if the patient has not recovered from side-effects associated with that investigational product
Description

Participation in another clinical study in which an investigational product was received within 14 days before the first dose in this study, or at any time if the patient has not recovered from side-effects associated with that investigational product

Data type

boolean

Alias
UMLS CUI-1
C2348568
Administration of LDAC is clinically contraindicated
Description

Administration of LDAC is clinically contraindicated

Data type

boolean

Alias
UMLS CUI-1
C1301624
UMLS CUI-2
C0010711
Patients with AML of FAB M3 classification Acute Promyelocytic Leukaemia (APL)
Description

Patients with AML of FAB M3 classification Acute Promyelocytic Leukaemia (APL)

Data type

boolean

Alias
UMLS CUI-1
C0023487
Patients with blast crisis of chronic myeloid leukaemia
Description

Patients with blast crisis of chronic myeloid leukaemia

Data type

boolean

Alias
UMLS CUI-1
C0023473
UMLS CUI-2
C0005699
Back to the top of the page

Similar models

Eligibility AZD1152 and LDAC in AML

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Inclusion criteria
C1512693 (UMLS CUI-1)
consent
Item
Provision of written informed consent
boolean
C0021430 (UMLS CUI-1)
Age
Item
Newly diagnosed male or female patients aged 60 and over
boolean
C0001779 (UMLS CUI-1)
AML
Item
De Novo or Secondary AML
boolean
C0023467 (UMLS CUI-1)
Patient not eligible for Induction therapy
Item
Not eligible for intensive induction with anthracycline-based combination chemotherapy as a result of at least one of the following: Age >=75 years; Adverse cytogenetics, e.g., as defined by the MRC Prognostic Groupings; WHO performance status >2; Organ dysfunction arising from significant co-morbidities not directly linked to leukaemia
boolean
C3242266 (UMLS CUI-1)
C0600558 (UMLS CUI-2)
Item Group
Exclusion criteria
C0680251 (UMLS CUI-1)
other trial
Item
Participation in another clinical study in which an investigational product was received within 14 days before the first dose in this study, or at any time if the patient has not recovered from side-effects associated with that investigational product
boolean
C2348568 (UMLS CUI-1)
Contraindication LDAC
Item
Administration of LDAC is clinically contraindicated
boolean
C1301624 (UMLS CUI-1)
C0010711 (UMLS CUI-2)
AML M3 APL
Item
Patients with AML of FAB M3 classification Acute Promyelocytic Leukaemia (APL)
boolean
C0023487 (UMLS CUI-1)
CML blast crisis
Item
Patients with blast crisis of chronic myeloid leukaemia
boolean
C0023473 (UMLS CUI-1)
C0005699 (UMLS CUI-2)
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial